Navigation Links
Pozen Announces Positive Outcome for PA 325

Administration, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for conditions such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The company's common stock is traded on The

Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: *www.pozen.com*.

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitiv
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Pozen Announces Positive Outcome for
(Date:8/27/2014)... BOSTON , Aug. 27, 2014  Columbia Laboratories, ... Company"), a provider of pharmaceutical development, clinical trial manufacturing, ... industry, today announced that it will participate at the ... Investment Conference, to be held in New ... conference at 11:15am on September 9, 2014 at the ...
(Date:8/27/2014)... China , Aug. 27, 2014  Amerigen Pharmaceuticals ... ("Menovo") today announced they had entered into a collaboration ... the United States market. Under ... jointly develop products for Amerigen to commercialize in ... responsible for manufacturing API and finished product whereas Amerigen ...
(Date:8/27/2014)... 2014 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") ... financial results for its third quarter of fiscal 2014: ... , Revenue of $1,291,378, a 13% decrease over the ... for the quarter of $240,156 compared to net income of ... For the nine months ended June 30, 2014: ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3
(Date:8/27/2014)... play a key role in inflaming blood vessels and ... study at UCLA demonstrates that they may also contribute ... the small blood vessels in the lungs. , Using ... mimicking part of the main protein in high-density lipoprotein ... production of oxidized lipids in pulmonary hypertension. They also ...
(Date:8/27/2014)... 27, 2014 The federal judge overseeing ... has extended the deadline for plaintiffs to enroll in ... Order issued by U.S. District Judge David Katz of ... in the DePuy ASR Settlement Program must do so ... ASR Hip Implant Products Liability Litigation – MDL 2197) ...
(Date:8/27/2014)... Ticket Down is a dependable source for authentic ... Miami. The Brazilian national soccer team will tangle with ... Life Stadium in Miami Gardens, Florida. The two South ... Cup earlier this year when Brazil got the 2-1 win, ... Federation announced earlier this week that Neymar would return from ...
(Date:8/27/2014)... 27, 2014 Connor Sports has ... World Cup in Spain at the Barcelona, Bilbao, Gran ... FIBA Equipment & Venue Centre Partner since 1994 and Official ... six courts will bear the Connor Sports logo and tagline ... globe on the ESPN broadcasts of the FIBA World Cup. ...
(Date:8/27/2014)... Philadelphia, PA (PRWEB) August 27, 2014 ... co-winner of this year’s 87th Annual Scripps National Spelling ... 2014 for a tour of internationally renowned Wills Eye ... would like to be an ophthalmologist one day. , ... simulated eye surgery and the latest hi-tech visual diagnostic ...
Breaking Medicine News(10 mins):Health News:Protein in 'good cholesterol' may be a key to treating pulmonary hypertension 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 2Health News:DePuy ASR Settlement Enrollment Deadline Extended Until September 30, 2014, Bernstein Liebhard LLP Reports 3Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Cuts Ticket Prices on World Cup Rematch of Colombia vs. Brazil at Sun Life Stadium in Miami on Sept. 5th 2Health News:Brazil vs. Colombia Tickets in Miami, FL: Ticket Down Cuts Ticket Prices on World Cup Rematch of Colombia vs. Brazil at Sun Life Stadium in Miami on Sept. 5th 3Health News:Connor Sports® Provides Six Custom Courts for 2014 FIBA World Cup - Time-Lapse Video of FIBA Courts Production Released 2Health News:Connor Sports® Provides Six Custom Courts for 2014 FIBA World Cup - Time-Lapse Video of FIBA Courts Production Released 3Health News:Scripps National Spelling Bee Co-Champion and Aspiring Ophthalmologist Coming to Wills Eye Hospital in Philadelphia 2
... SANDUSKY, Ohio, April 30 In celebration of the 20th ... Chapter of the American Red Cross is teaming up with ... who want to be among the first riders of Magnum,s ... to the 36 highest bidders, with bids starting at $75. ...
... a complex process of the central nervous system ... fact, olfactory dysfunction is seen in various central ... as Parkinson,s disease, schizophrenia, Alzheimer,s disease and multiple ... disease that sometimes involves the central nervous system ...
... Inc., a leading manufacturer of cold chain management ... of all products that help ensure product efficacy ... designed to monitor and record temperature, and can ... and pharmaceuticals.Many vaccines and pharmaceuticals have temperature sensitivity ...
... YORK and NASSAU, The Bahamas, April 30 ... of Fincor (FINC) through a 1:1 share split. Prospero ... Technologies enlarges thru Fincor its portfolio with the new ... the WETTECH and Advanced Cavitation Technologies. Prospero ...
... Computers are increasingly used in daily life: 56 percent ... percent of households own one. Arthritis is a leading ... may have difficulty performing physically demanding jobs, and may ... computer use. Computer use is a risk factor for ...
... measure the level of adoption of select process ... enhances its educational mission through its Patient Safety ... Pennsylvania Patient Safety Authority issued its 2008 Annual ... adoption of some process and safety practices related ...
Cached Medicine News:Health News:Firelands Chapter of the American Red Cross to Auction First Rides on Magnum's 20th Anniversary 2Health News:Decrease in sense of smell seen in lupus patients 2Health News:DeltaTRAK Responds to Swine Flu Outbreak With Full Line of Products for Temperature Sensitive Vaccines 2Health News:Prospero Group (PRPG) and Fincor (FINC) Made a Share Transfer and Enter the Market with ACTRx a New Malaria and Dengue Fever Treatment 2Health News:Computer use significantly affected by arthritis 2Health News:Computer use significantly affected by arthritis 3Health News:Pennsylvania Patient Safety Authority Issues Annual Report for 2008 2Health News:Pennsylvania Patient Safety Authority Issues Annual Report for 2008 3Health News:Pennsylvania Patient Safety Authority Issues Annual Report for 2008 4Health News:Pennsylvania Patient Safety Authority Issues Annual Report for 2008 5Health News:Pennsylvania Patient Safety Authority Issues Annual Report for 2008 6
... has two sensors and a black band ... optimal placement in relation to the UES., ... pH monitoring. , ,Alpine's VersaFlex catheters ... the market (4.7 French), and are the ...
... pH catheters are efficient, economical, eliminate ... greater patient comfort during the test ... systems have been designed to use ... accurate room-temperature calibration. The temperature correction ...
FLEXILOG spare part....
FLEXILOG spare part....
Medicine Products: